我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
6
5 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
5
83.3%
已完成
1
16.7%
暂无批准数据
- LivaNova PLC has launched its Essenz Perfusion System in China after receiving regulatory approval from the National Medical Products Administration, targeting the world's second-largest heart-lung machine market. - The next-generation cardiopulmonary platform has supported over 100,000 patients globally since its 2023 launch and offers real-time monitoring with patient-tailored perfusion capabilities. - China represents a significant growth opportunity with 330 million individuals affected by cardiovascular disease and over 700 hospitals equipped for cardiac surgery. - The system addresses the projected 185,000 adult and 23,500 pediatric extracorporeal circulation procedures expected in China for 2025.
